IPOGrid
0001822935
IPO filing research
Healthcare Capital Corp/DE
Blank Checks
ipo
priced
425
Healthcare Capital Corp/DE IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: 425 on 2022-02-18.
Filing Timeline
SEC EDGAR
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2022-02-18 · 0001213900-22-008397
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2022-02-17 · 0001213900-22-008176
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2022-02-15 · 0001213900-22-007946
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
Alpha Tau Medical Ltd. announced a new research collaboration with The University of Texas MD Anderson Cancer Center to evaluate the potential of Alpha DaRT to enhance immune stimulation in breast cancer treatment. The study explores combining Alpha DaRT with DNA-repair inhibitors and immune checkpoint inhibitors. This follows Alpha Tau's July 2021 merger agreement with Healthcare Capital Corp. (HCCC), which aims to make Alpha Tau a Nasdaq-listed public company. The filing also references ongoing regulatory and business combination processes.
2022-01-20 · 0001213900-22-002744
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2022-01-19 · 0001213900-22-002671
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
Alpha Tau Medical Ltd. is advancing its business combination with Healthcare Capital Corp. (HCCC), focusing on the Alpha DaRT technology for cancer treatment. The current filing highlights clinical trial progress, including FDA Breakthrough Device Designations for skin and GBM, and outlines a strategic path for pivotal trials. It emphasizes the technology's potential, safety profile, and manufacturing logistics, while noting risks related to regulatory approvals and clinical outcomes.
2022-01-12 · 0001193125-22-007758
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
Alpha Tau Medical Ltd. announced positive results from its first U.S. clinical trial of Alpha DaRT for malignant skin and soft tissue cancers, with all 10 patients achieving a complete response at 12 weeks and no serious adverse events. The company highlighted these findings as a key milestone toward advancing its U.S. pivotal trial and noted ongoing interest from clinicians. The filing also references its pending business combination with Healthcare Capital Corp. (HCCC), which would list Alpha Tau on Nasdaq.
2022-01-10 · 0001213900-22-001208
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
Alpha Tau Medical Ltd. announced the completion of enrollment in a pivotal clinical trial for its Alpha DaRT therapy in Japanese patients with recurrent head and neck cancer. The trial, conducted in collaboration with HekaBio K.K., has yielded preliminary encouraging results, with plans to submit data for marketing approval via Japan's shonin pathway. The company also reiterated its focus on advancing the therapy globally, including potential U.S. trials, following its recent merger agreement with Healthcare Capital Corp. (HCCC).
2022-01-03 · 0001213900-22-000245
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
Alpha Tau Medical Ltd. announced the enrollment of the first patient in a combination trial of Alpha DaRT with pembrolizumab (Keytruda) for recurrent head and neck squamous cell carcinoma. This follows the completion of a previous US pilot trial for skin cancer, highlighting ongoing clinical development of its alpha-radiation therapy. The company remains on track for a business combination with Healthcare Capital Corp. (HCCC), expected to list on Nasdaq.
2021-11-03 · 0001213900-21-056434
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
Alpha Tau Medical Ltd. announced the completion of enrollment in its first U.S. clinical trial for Alpha DaRT, achieving the primary objective of demonstrating feasibility for treating skin cancer. The trial showed no serious adverse events, with treatment-related effects aligning with prior trials. The company anticipates advancing to a pivotal U.S. trial in 2022, following its merger with Healthcare Capital Corp. (HCCC) and potential FDA regulatory pathways.
2021-10-25 · 0001213900-21-054436
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
Alpha Tau Medical Ltd. announced receiving FDA Breakthrough Device Designation for Alpha DaRT treatment of recurrent glioblastoma multiforme (GBM), marking a key regulatory milestone. This follows prior Breakthrough Device Designation for skin cancer. The company is progressing toward a business combination with Healthcare Capital Corp. (HCCC), which would list Alpha Tau on Nasdaq. The FDA designation aims to expedite clinical development and regulatory review for GBM treatment.
2021-10-13 · 0001213900-21-052482
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
2021-07-08 · 0001213900-21-036059
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 425 in the pre-IPO sequence.
Alpha Tau Medical Ltd. announced a business combination with Healthcare Capital Corp. (HCC), creating a publicly traded company focused on alpha radiation therapy for solid tumors. The deal implies a $1 billion equity value, with $367 million in gross proceeds from HCC's trust and a $92 million PIPE. Alpha Tau's Alpha DaRT technology, granted FDA Breakthrough Device Designation, will leverage funds for clinical expansion, R&D, manufacturing, and commercialization. The combined entity expects to list on Nasdaq by year-end 2021, with Alpha Tau's management retaining control and HCC's Dr. David M. Milch joining the board.
2021-07-08 · 0001193125-21-210580
425
supplemental
425
Pre-IPO filing captured from the SEC submission timeline.
Follows 424B4 in the pre-IPO sequence.
Alpha Tau Medical Ltd. is preparing for a business combination with Healthcare Capital Corp. (HCCC) as outlined in a Rule 425 filing. The document serves as an informational presentation for potential investors, detailing the proposed merger, Alpha Tau's proprietary cancer radiotherapy technology (Alpha DaRT), and the potential for transforming solid tumor treatment. The filing includes forward-looking statements, disclaimers about the不确定性 of projections, and highlights the company's clinical trial results and intellectual property. It also notes the involvement of placement agents and the need for investors to consult their own advisors.
2021-07-08 · 0001193125-21-210328
424B4
priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
Follows EFFECT and confirms the priced prospectus.
2021-01-20 · 0001213900-21-003051
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows CERT and marks the registration effective.
2021-01-14 · 9999999995-21-000151
CERT
inactive
CERT
Pre-IPO filing captured from the SEC submission timeline.
Follows 8-A12B in the pre-IPO sequence.
2021-01-14 · 0001354457-21-000053
8-A12B
effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows S-1/A and registers the class of securities for exchange listing.
2021-01-13 · 0001213900-21-001968
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
2021-01-13 · 0001213900-21-001944
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
2021-01-11 · 0001213900-21-001412
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS in the pre-IPO sequence.
2020-12-21 · 0001213900-20-043631
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
2020-10-13 · 0001213900-20-030902
Comparable Deals
1 comparable deal
FinancialsLast 18 months
Only 0 strict matches; expanded to 1 using nearest neighbors.
Recent News
No recent news stored for this issuer.